Beyond the Horizon: the Newly Found Sinner Disturbing Mesenchymal Stromal Niche
Xi Zhang
DOI: https://doi.org/10.1097/bs9.0000000000000119
2022-01-01
Blood Science
Abstract:Hematopoietic stem-cell transplantation (HSCT) is an important, potentially curative therapeutic option for hematological malignancies. However, poor and slow hematopoietic reconstitution remains a significant complication, which is correlated with abnormal hematopoietic stem-cell (HSC) function. The maintenance and the preservation of HSC functional properties are supported by a highly specialized microenvironment within the bone marrow (BM), in which BM-derived mesenchymal stem cells (BMSCs) serve as the essential structural and functional basis for constituting the BM microenvironment. Damage, such as that due to chemotherapy, radiotherapy or inflammation, delays hematopoietic recovery or causes hematopoiesis dysfunction or failure, seriously affecting HSCT efficacy.1 The key to remodeling and repairing the BM microenvironment lies in the repair of the niche structure by cellular therapies which include BMSCs. Research has increasingly confirmed that the most crucial functions of BMSCs are to maintain the turnover of the BM stroma and skeletal tissues and to provide critical hematopoietic support.2 However, the underlying mechanisms that regulate these different functions are not well known. In the recent BLOOD publication, the Dr. Zhao and Dr. Jiang group revealed that the retinoic acid-inducible gene I (RIG-I) plays a substantial role in regulating the stromal niche for hematopoietic reconstitution.3 All-trans retinoic acid (ATRA) and inflammation stress upregulated RIG-I expression, thus damaging the clonogenicity, the bone-forming ability of BMSCs and the supporting function in the stromal niche; mechanistically, this is achieved by suppressing the antioxidant impact of nuclear factor erythroid 2-related factor 2 (NRF2), thereby generating an excessive accumulation of reactive oxygen species (ROS) which damages BMSCs in their support of the stromal niche. Genetic inhibition of RIG-I sustains NRF2 expression and reduces ROS levels, thus preserving their essential features in supporting HSC engraftment. Moreover, the recovery of niche function by RIG-I inhibition could enhance emergency myelopoiesis for innate immunity during HSCT. It is of interest that RIG-I deletion could effectively rescue ATRA-induced osteoporosis, recovering the clonogenicity and osteogenetic capacities of BMSCs under ATRA treatment. In brief, this study clarified a key mechanism, which the RIG-I-NRF2 axis could be a switch for endogenous stromal niche damage within the BMSCs in hematopoietic reconstruction and engraftment after HSCT; this would provide a reliable target to improve transplantation efficacy and protect against inflammation after HSCT, quite apart from putting forward a new direction for rescued chemotherapy-induced osteoporosis. A normal stromal niche structure and function are essential for maintaining hematopoiesis. Dr. Zhao and Dr. Jiang group work has clarified sustained mechanisms for BMSCs in the recovery of the BM environment with the final purpose of improving hematopoiesis and immune reconstruction after HSCT, suggesting that co-transplantation with MSCs and HSCs could offer an optional treatment to promote hematopoietic and immune reconstitution after HSCT. However, much remains unknown about the effect of clinical treatment (including immunosuppressants) on the efficacy of MSC therapy before and after HSCT. Previous work from Cheng and Huang's group showed that antioxidant therapy protects HSC function and promotes HSCT.4,5 This study further showed that antioxidant therapy can also benefit HSCT by rescuing the damaged BMSC niche. Genetic inhibition of RIG-I might be able to enhance MSC function in supporting HSCT, which can be applied to the next generation of MSC-based cell therapy.3 To avoid the limitations of single therapy, whether there is any possibility of combining medication and cellular therapy to obtain the best therapeutic effect is a problem yet to be solved. The findings in this study provide the latest significant exploration for solving this problem, with RIG-1 inhibition as a target for the recovery of BMSC function related to supporting bone formation and the stromal niche after HSCT. In addition, owing to discrepancies between mouse and human species, translational research on the intervention of RIG-I on BMSC therapy to improve hematopoiesis after HSCT needs further emphasis. This study elicited additional questions. For example, basic and clinical studies have repeatedly confirmed that MSCs could reduce the incidence of graft-versus-host disease (GVHD) without increasing the risks of leukemia recurrence and infection,6 but whether RIG-I inhibition participates in the immunoregulation of BMSCs remains unknown, which puts forward the concept of dominant functional MSCs. Stem-cell factor (SCF) and CXCL12-expressing BMSCs were proposed as the critical niche in HSC maintenance.7–9 A previous study by Dr. Zhao revealed that a small N-Cadherin-expressing BMSC subpopulation supports chemoresistant HSCs for regeneration.10 In this article, parathyroid hormone (PTH) treatment reduced bone loss but not HSCT failure, indicating that osteogenesis and the HSC-niche function of MSCs might be dichotomously regulated. Identifying and expanding the MSCs functional subpopulations in supporting osteoblasts and HSCT hold great potential significance in MSC-based cell therapy. Based on the above findings, is there a specific marker or group of markers to help researchers define or isolate the targeted functional BMSCs, apart from the respective regulatory mechanisms and optimizing preparation strategies? These questions need more translational research to push applications to the clinic and the benefit of patients. Overall, this study has identified the crucial sinner, RIG-1, in disturbing mesenchymal stromal niche function; RIG-1 inhibition could help BMSCs to better support HSC engraftment during transplantation under ATRA treatment and inflammation. Further investigations are warranted to explore other potential mechanisms by which BMSCs affect osteoblasts for bone formation as well as HSC regulation, and to understand heterogeneity among MSCs. In this respect, further studies are needed to explore dominant functional MSCs, thereby establishing a foundation for the development of MSC-based cellular therapies for different medical indications following HSCT.